دورية أكاديمية
Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma.
| العنوان: | Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma. |
|---|---|
| المؤلفون: | Konstantinopoulos PA; Division of Gynecologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.; Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Waggoner S; Department of Reproductive Medicine, Case Western Reserve University School of Medicine, University Hospitals of Cleveland, Cleveland, Ohio., Vidal GA; Division of Medical Oncology, West Cancer Center, Memphis, Tennessee., Mita M; Department of Hematology and Oncology, Cedars-Sinai Medical Center, Los Angeles, California., Moroney JW; Section of Gynecologic Oncology, Department of Obstetrics & Gynecology, University of Chicago Medicine, Chicago, Illinois., Holloway R; Division of Gynecologic Oncology, Florida Hospital Gynecologic Oncology, Florida Hospital Cancer Institute, Orlando.; Global Robotics Institute, Orlando, Florida., Van Le L; Department of Obstetrics & Gynecology, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill., Sachdev JC; Division of Hematology and Oncology, Virginia G. Piper Cancer Center Clinical Trials, HonorHealth Research Institute, Scottsdale, Arizona.; Translational Genomics Research Institute, Scottsdale, Arizona., Chapman-Davis E; Weill Cornell Medicine, Department of Obstetrics and Gynecology, Cornell University, New York, New York., Colon-Otero G; Department of Internal Medicine, Mayo Clinic, Jacksonville, Florida., Penson RT; Division of Hematology-Oncology, Department of Medicine, Massachusetts General Hospital, Boston., Matulonis UA; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Kim YB; Department of Obstetrics and Gynecology, Tufts Medical Center, Boston, Massachusetts., Moore KN; Stephenson Cancer Center, Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center, Oklahoma City.; Sarah Cannon Research Institute, Nashville, Tennessee., Swisher EM; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Washington, Seattle., Färkkilä A; Department of Obstetrics and Gynaecology, Helsinki University Hospital, University of Helsinki, Helsinki, Finland., D'Andrea A; Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Stringer-Reasor E; Division of Hematology/Oncology, Department of Medicine, The University of Alabama at Birmingham., Wang J; Department of Research & Early Development, TESARO: A GSK Company, Waltham, Massachusetts., Buerstatte N; Department of Clinical Operations, TESARO: A GSK Company, Waltham, Massachusetts., Arora S; Department of Biostatistics, TESARO: A GSK Company, Waltham, Massachusetts., Graham JR; Department of Clinical Science, TESARO: A GSK Company, Waltham, Massachusetts., Bobilev D; Department of Clinical Science, TESARO: A GSK Company, Waltham, Massachusetts., Dezube BJ; Department of Clinical Science, TESARO: A GSK Company, Waltham, Massachusetts., Munster P; Helen Diller Family Comprehensive Cancer Center, Department of Medicine, University of California, San Francisco, Medical Center at Mount Zion, San Francisco. |
| المصدر: | JAMA oncology [JAMA Oncol] 2019 Aug 01; Vol. 5 (8), pp. 1141-1149. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Medical Association Country of Publication: United States NLM ID: 101652861 Publication Model: Print Cited Medium: Internet ISSN: 2374-2445 (Electronic) Linking ISSN: 23742437 NLM ISO Abbreviation: JAMA Oncol Subsets: PubMed not MEDLINE; MEDLINE |
| أسماء مطبوعة: | Original Publication: Chicago, Il : American Medical Association, [2015]- |
| مستخلص: | Importance: Patients with recurrent ovarian carcinoma frequently develop resistance to platinum-based chemotherapy, at which time treatment options become limited. Objective: To evaluate the poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitor niraparib combined with pembrolizumab in patients with recurrent ovarian carcinoma. Design, Setting, and Participants: The TOPACIO/KEYNOTE-162 (Niraparib in Combination With Pembrolizumab in Patients With Triple-Negative Breast Cancer or Ovarian Cancer) trial, an open-label, single-arm phases 1 and 2 study enrolled women with advanced or metastatic triple-negative breast cancer (TNBC) or recurrent ovarian carcinoma, irrespective of BRCA mutation status. Median follow-up was 12.4 months (range, 1.2 to ≥23.0 months). Data were collected from April 15, 2016, through September 4, 2018, with September 4, 2018, as a data cutoff, and analyzed from September 4, 2018, through January 30, 2019. Interventions: The recommended phase 2 dose (RP2D) was 200 mg of oral niraparib once daily and 200 mg of intravenous pembrolizumab on day 1 of each 21-day cycle. Main Outcomes and Measures: The primary objectives of phase 1 were to evaluate dose-limiting toxic effects and establish the RP2D and dosing schedule. The primary objective of phase 2 was to assess objective response rate (ORR; complete plus partial responses). Results from the phase 1 ovarian carcinoma and TNBC cohorts and phase 2 ovarian carcinoma cohort are reported. Because of the similarity in the phase 1 and 2 ovarian carcinoma populations, the data were pooled to perform an integrated efficacy analysis. Results: Fourteen patients (9 with ovarian carcinoma and 5 with TNBC) in phase 1 and 53 patients with ovarian carcinoma in phase 2 were enrolled, for a pooled ovarian carcinoma cohort of 62 patients (median age, 60 years [range, 46-83 years]). In the integrated efficacy phases 1 and 2 ovarian carcinoma population (60 of 62 evaluable patients), ORR was 18% (90% CI, 11%-29%), with a disease control rate of 65% (90% CI, 54%-75%), including 3 (5%) with confirmed complete responses, 8 (13%) with confirmed partial responses, 28 (47%) with stable disease, and 20 (33%) with progressive disease. The ORRs were consistent across subgroups based on platinum-based chemotherapy sensitivity, previous bevacizumab treatment, or tumor BRCA or homologous recombination deficiency (HRD) biomarker status. Median duration of response was not reached (range, 4.2 to ≥14.5 months). At data cutoff, 2 patients with a response and 1 patient with stable disease continued to receive treatment. Conclusions and Relevance: Niraparib in combination with pembrolizumab is tolerable, with promising antitumor activity for patients with ovarian carcinoma who have limited treatment options regardless of platinum status, biomarker status, or prior treatment with bevacizumab. Responses in patients without tumor BRCA mutations or non-HRD cancers were higher than expected with either agent as monotherapy. Trial Registration: ClinicalTrials.gov identifier: NCT02657889. |
| التعليقات: | Comment in: JAMA Oncol. 2020 Mar 1;6(3):441. (PMID: 31876893) Comment in: JAMA Oncol. 2020 Mar 1;6(3):440-441. (PMID: 31876918) Comment in: Ann Transl Med. 2019 Dec;7(Suppl 8):S308. (PMID: 32016027) |
| References: | Gynecol Oncol. 2005 Jun;97(3):862-9. (PMID: 15894355) N Engl J Med. 2016 Dec;375(22):2154-2164. (PMID: 27717299) N Engl J Med. 2009 Jul 9;361(2):123-34. (PMID: 19553641) Invest New Drugs. 2017 Dec;35(6):751-765. (PMID: 28303528) Sci Rep. 2019 Feb 12;9(1):1853. (PMID: 30755715) Lancet Oncol. 2011 Sep;12(9):852-61. (PMID: 21862407) J Clin Oncol. 2010 May 20;28(15):2512-9. (PMID: 20406929) Ann Oncol. 2015 Dec;26(12):2375-91. (PMID: 26371282) Eur J Obstet Gynecol Reprod Biol. 2013 Jan;166(1):94-8. (PMID: 23088893) Gynecol Oncol. 2015 Jun;137(3):386-91. (PMID: 25818403) Nat Commun. 2017 Nov 24;8(1):1751. (PMID: 29170499) Cancer Res. 2019 Jan 15;79(2):311-319. (PMID: 30482774) Lancet Oncol. 2013 Aug;14(9):882-92. (PMID: 23810788) Eur J Cancer. 2009 Jan;45(2):228-47. (PMID: 19097774) Ann Oncol. 2019 Jul 1;30(7):1080-1087. (PMID: 31046082) J Clin Oncol. 2014 May 1;32(13):1302-8. (PMID: 24637997) Clin Cancer Res. 2017 Jul 15;23(14):3711-3720. (PMID: 28167507) Gynecol Oncol. 2017 Nov;147(2):267-275. (PMID: 28882436) J Clin Oncol. 2013 Oct 1;31(28):3592-9. (PMID: 24002522) Gynecol Oncol. 2016 Feb;140(2):199-203. (PMID: 26723501) Ann Oncol. 2018 Aug 1;29(8):1784-1792. (PMID: 29767688) |
| معلومات مُعتمدة: | P30 CA013148 United States CA NCI NIH HHS |
| سلسلة جزيئية: | ClinicalTrials.gov NCT02657889 |
| تواريخ الأحداث: | Date Created: 20190614 Latest Revision: 20231012 |
| رمز التحديث: | 20240829 |
| مُعرف محوري في PubMed: | PMC6567832 |
| DOI: | 10.1001/jamaoncol.2019.1048 |
| PMID: | 31194228 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2374-2445 |
|---|---|
| DOI: | 10.1001/jamaoncol.2019.1048 |